For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The ...

公司融资活动 - Terns Pharmaceuticals 宣布对其增发后的承销公开发行进行定价 发行16,250,000股普通股 每股公开发行价格为40.00美元[1] - 此次发行预计在扣除承销折扣和佣金及其他费用前 总收益为6.5亿美元[1] - 公司授予承销商一项30天期权 可额外购买最多2,437,500股普通股[1] - 此次发行预计于2025年12月11日结束 取决于惯例成交条件[1] 发行承销商 - 此次发行的联席账簿管理人为Jefferies、TD Cowen和Leerink Partners[2] - 联席经理为Mizuho、Citizens Capital Markets和Oppenheimer & Co.[2] 募集资金用途 - 公司计划将此次发行的净收益用于资助关键候选产品的研究、临床试验、开发和制造 包括TERN-701[3] - 资金还将用于为TERN-701潜在未来商业发布做准备的初始活动 以及用于营运资金和一般公司用途[3] 公司业务与产品 - Terns Pharmaceuticals 是一家临床阶段肿瘤学公司[6] - 其主要项目TERN-701是一种高选择性、变构的BCR-ABL抑制剂 具有潜在的最佳疾病谱 可能显著改善现有CML（慢性髓性白血病）治疗方法的疗效、安全性和便利性[6]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best performers on Monday. Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to test the efficacy of drug candidate, TERN-701, in patients with previously treated chronic myeloid leukemia (CML). At intra-day trading, the stock climbed to its highest price of $45 before trimming gains to finish the ...

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.As of the cutoff date of September 13, 2025, 63 patients were enrolled.DataOf 38 efficacy-evaluable patients, the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks, with 64% (18/28) achieving MMR and 100% (10/10) ma ...